Fig 1.
Study flow chart.
Table 1.
Baseline characteristics of study population.
Table 2.
High output cardiac failure group summarized data.
Fig 2.
Hemoglobin level variation during bevacizumab treatment.
Baseline hemoglobin level represents the summary of all hemoglobin values 3 months before starting bevacizumab treatment. The dotted line is the fitted regression line (Linear mixed effects model).
Fig 3.
Blood unit requirement during bevacizumab treatment.
Baseline blood unit level represents the total number of units received along 3 months before starting bevacizumab treatment. The dotted line is the fitted regression lines (Poisson mixed effects model).
Fig 4.
Epistaxis severity score variation during bevacizumab treatment.
Baseline score represents epistaxis severity 3 months before starting bevacizumab treatment. The dotted line is the fitted regression line (Linear mixed effects model).